decisionhealth Newsletters, Part B News - 2007 Issue 1 (January)
MedPAC: Bundles, middlemen top ASP challenges you face
Subscribe or sign in to view the full article.
Article Overview
This piece reviews MedPAC’s analysis of major concerns in Medicare Part B drug purchasing under the average sales price framework. It is relevant to providers, billing and reimbursement staff, and pharmacy or practice administrators who track how manufacturer discounts, purchasing intermediaries, and bundled sales can affect payment accuracy and drug acquisition costs. The article also highlights MedPAC’s single recommendation to Congress and its discussion of broader market effects on physician-office drug administration.
Why This Topic Matters
Understanding how ASP-based reimbursement is affected by manufacturer pricing practices and intermediary markups can help practices evaluate whether reimbursement aligns with their drug acquisition costs. The topic matters for organizations that administer Part B drugs and for stakeholders monitoring Medicare payment policy.
What You Will Learn
- The main policy concerns MedPAC identified in the ASP drug payment environment
- How bundled sales and intermediary transactions can affect reimbursement accuracy
- Why the article discusses manufacturer discounts and pricing transparency
- What broader site-of-care and access issues MedPAC noted in relation to Part B drugs
Who Should Read This
- Physician practice administrators
- Medical coders and billers
- Revenue cycle staff
- Pharmacy buyers and purchasing managers
- Healthcare policy analysts
- Oncology and infusion practice staff
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com